PMID- 37264630
OWN - NLM
STAT- Publisher
LR  - 20230602
IS  - 1724-6032 (Electronic)
IS  - 1129-7298 (Linking)
DP  - 2023 Jun 1
TI  - Perforated intravenous catheter design is acceptable for the administration of 
      contrast-enhanced computed tomography administration in cancer patients: Results 
      of a pilot randomised controlled trial.
PG  - 11297298231171422
LID - 10.1177/11297298231171422 [doi]
AB  - BACKGROUND: Optimising first time success of peripheral intravenous catheter 
      (PIVC) insertion and reducing intravenous (IV) complications in cancer patients 
      undergoing contrast-enhanced computed tomography (CT) is vital to ensure vascular 
      access preservation and diagnostic accuracy. The aim of this study was to test 
      the feasibility of a randomised controlled trial (RCT) evaluating a novel 
      perforated PIVC compared to a standard PIVC. METHODS: A single centre, 
      parallel-group, pilot RCT was conducted between March and May 2020. Adult 
      participants diagnosed with cancer were randomised to a non-perforated PIVC 
      (standard care) or a PIVC with a novel perforated design (intervention) for the 
      administration of IV contrast. There were two primary outcomes: (1) feasibility 
      of an adequately powered RCT with pre-established criteria; and (2) all-cause 
      PIVC failure. Secondary outcomes included: first insertion success, modes of PIVC 
      failure, dwell time, contrast injection parameters (volume and injection rate), 
      contrast enhancement, radiographer satisfaction and adverse events. RESULTS: 
      Feasibility outcomes were met, except for eligibility (⩾90%) and recruitment 
      (⩾90%). In total, 166 participants were screened, 128 (77%) were eligible and of 
      these 101/128 (79%) were randomised; 50 to standard care and 51 to intervention. 
      First time insertion rate was 94% (47/50) in standard care and 90% (46/50) in 
      intervention. The median dwell time was 37 minutes (interquartile range (IQR): 
      25-55) in standard care and 35 minutes (IQR: 25-60) in the intervention group. 
      There was one PIVC failure, a contrast media extravasation, in the intervention 
      group (1/51; 2%). The desired contrast injection rate was not achieved in 4/101 
      (4%) of participants; two from each group. Radiographers were satisfied with the 
      contrast flow rate. CONCLUSIONS: This pilot RCT suggests perforated PIVCs provide 
      expected flow rate, with no evidence of differences in contrast enhancement to 
      non-perforated PIVCs. The feasibility of conducting a larger powered RCT was 
      demonstrated.
FAU - Gavin, Nicole C
AU  - Gavin NC
AUID- ORCID: 0000-0002-0828-9852
AD  - School of Nursing and Centre for Healthcare Transformation, Queensland University 
      of Technology, Kelvin Grove, QLD, Australia.
AD  - Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, 
      Australia.
AD  - Alliance for Vascular Access Teaching and Research (AVATAR), School of Pharmacy 
      and Medical Sciences, Griffith University, Nathan, QLD, Australia.
FAU - Wignall, Elizabeth
AU  - Wignall E
AD  - Department of Medical Imaging, Royal Brisbane and Women's Hospital, Herston, QLD, 
      Australia.
FAU - Marsh, Nicole
AU  - Marsh N
AD  - School of Nursing and Centre for Healthcare Transformation, Queensland University 
      of Technology, Kelvin Grove, QLD, Australia.
AD  - Alliance for Vascular Access Teaching and Research (AVATAR), School of Pharmacy 
      and Medical Sciences, Griffith University, Nathan, QLD, Australia.
AD  - Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, 
      Herston, QLD, Australia.
FAU - Marquart, Louise
AU  - Marquart L
AD  - School of Public Health, University of Queensland, Herston, QLD, Australia.
AD  - Queensland Institute of Medical Research Berghofer Medical Research Institute, 
      Herston, QLD, Australia.
FAU - Dobeli, Karen L
AU  - Dobeli KL
AD  - Department of Medical Imaging, Royal Brisbane and Women's Hospital, Herston, QLD, 
      Australia.
FAU - O'Brien, Catherine
AU  - O'Brien C
AD  - Department of Medical Imaging, Royal Brisbane and Women's Hospital, Herston, QLD, 
      Australia.
AD  - Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, 
      Herston, QLD, Australia.
FAU - Verderosa, Anthony D
AU  - Verderosa AD
AD  - School of Biomedical Sciences and Centre for Immunology and Infection Control, 
      Queensland University of Technology, Kelvin Grove, QLD, Australia.
FAU - Totsika, Makrina
AU  - Totsika M
AD  - School of Biomedical Sciences and Centre for Immunology and Infection Control, 
      Queensland University of Technology, Kelvin Grove, QLD, Australia.
FAU - Keogh, Samantha
AU  - Keogh S
AUID- ORCID: 0000-0002-2797-4388
AD  - School of Nursing and Centre for Healthcare Transformation, Queensland University 
      of Technology, Kelvin Grove, QLD, Australia.
AD  - Alliance for Vascular Access Teaching and Research (AVATAR), School of Pharmacy 
      and Medical Sciences, Griffith University, Nathan, QLD, Australia.
AD  - Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, 
      Herston, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20230601
PL  - United States
TA  - J Vasc Access
JT  - The journal of vascular access
JID - 100940729
SB  - IM
OTO - NOTNLM
OT  - Catheters
OT  - X-ray computed
OT  - contrast media
OT  - extravasation of diagnostic and therapeutic materials
OT  - neoplasm
OT  - randomised controlled trial
OT  - tomography
EDAT- 2023/06/02 06:42
MHDA- 2023/06/02 06:42
CRDT- 2023/06/02 03:42
PHST- 2023/06/02 06:42 [medline]
PHST- 2023/06/02 06:42 [pubmed]
PHST- 2023/06/02 03:42 [entrez]
AID - 10.1177/11297298231171422 [doi]
PST - aheadofprint
SO  - J Vasc Access. 2023 Jun 1:11297298231171422. doi: 10.1177/11297298231171422.